These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Management of older patients with multiple myeloma. Gay F; Palumbo A Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387 [TBL] [Abstract][Full Text] [Related]
4. Treatment paradigms for the newly diagnosed patient with multiple myeloma. Greipp P Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097 [TBL] [Abstract][Full Text] [Related]
5. Novel agents in the frontline management of multiple myeloma. Loong HH Hematol Oncol Stem Cell Ther; 2008; 1(4):201-9. PubMed ID: 20058474 [TBL] [Abstract][Full Text] [Related]
6. Novel approaches to the management of myeloma. Rajkumar SV Oncology (Williston Park); 2005 Apr; 19(5):621-5. PubMed ID: 15948290 [TBL] [Abstract][Full Text] [Related]
7. Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials. Yaqub S; Ballester G; Ballester O Cancer Invest; 2013 Oct; 31(8):529-37. PubMed ID: 24083815 [TBL] [Abstract][Full Text] [Related]
8. Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report. Miyao K; Sakemura R; Sakai T; Tsushita N; Kato T; Niimi K; Ono Y; Sawa M Ann Hematol; 2014 Mar; 93(3):529-30. PubMed ID: 23820941 [No Abstract] [Full Text] [Related]
9. Novel agents for relapsed and/or refractory multiple myeloma. Thomas SK; Richards TA; Weber DM Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168 [TBL] [Abstract][Full Text] [Related]
10. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial. Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621 [TBL] [Abstract][Full Text] [Related]
13. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209 [TBL] [Abstract][Full Text] [Related]
14. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma. Badros A; Goloubeva O; Fenton R; Rapoport AP; Akpek G; Harris C; Ruehle K; Westphal S; Meisenberg B Clin Lymphoma Myeloma; 2006 Nov; 7(3):210-6. PubMed ID: 17229337 [TBL] [Abstract][Full Text] [Related]
15. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778 [TBL] [Abstract][Full Text] [Related]
16. Diagnosis and the current trends in multiple myeloma therapy. DmoszyĆska A Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817 [TBL] [Abstract][Full Text] [Related]